Cargando…

Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy

BACKGROUND: Influenza is a substantial cause of morbidity and mortality for Israel and the Palestinian territory. Given the extensive interaction between the two populations, vaccination in one population may indirectly benefit the other via reduced transmission. Due to the mobility and extensive co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamin, Dan, Kahana, Dor, Shahmoon, Edan, Fitzpatrick, Meagan C., Galvani, Alison P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358262/
https://www.ncbi.nlm.nih.gov/pubmed/34384411
http://dx.doi.org/10.1186/s12889-021-11601-2
_version_ 1783737299289243648
author Yamin, Dan
Kahana, Dor
Shahmoon, Edan
Fitzpatrick, Meagan C.
Galvani, Alison P.
author_facet Yamin, Dan
Kahana, Dor
Shahmoon, Edan
Fitzpatrick, Meagan C.
Galvani, Alison P.
author_sort Yamin, Dan
collection PubMed
description BACKGROUND: Influenza is a substantial cause of morbidity and mortality for Israel and the Palestinian territory. Given the extensive interaction between the two populations, vaccination in one population may indirectly benefit the other via reduced transmission. Due to the mobility and extensive contacts, Palestinians employed in Israel could be a prime target for vaccination. METHODS: To evaluate the epidemiological and the economic benefits conferred by vaccinating Palestinians employed in Israel, we developed a model of influenza transmission within and between Israel and the West Bank. We parameterized the contact patterns underlying transmission by conducting a survey among Palestinians employed in Israel, and integrating survey results with traffic patterns and socio-demographic data. RESULTS: Vaccinating 50% of Palestinian workers is predicted to reduce the annual influenza burden by 28,745 cases (95% CI: 15,031-50,717) and 37.7 deaths (95% CI: 19·9–65·5) for the Israeli population, and by 32,9900 cases (95% CI: 14,379-51,531) and 20.2 deaths (CI 95%: 9·8–31·5) for the Palestinian population. Further, we found that as the indirect protection was so substantial, funding such a vaccination campaign would be cost-saving from the Israeli Ministry of Health perspective. CONCLUSIONS: Offering influenza vaccination to Palestinians employed in Israel could efficiently reduce morbidity and mortality within both Israel and the Palestinian territory. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-11601-2.
format Online
Article
Text
id pubmed-8358262
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83582622021-08-12 Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy Yamin, Dan Kahana, Dor Shahmoon, Edan Fitzpatrick, Meagan C. Galvani, Alison P. BMC Public Health Research Article BACKGROUND: Influenza is a substantial cause of morbidity and mortality for Israel and the Palestinian territory. Given the extensive interaction between the two populations, vaccination in one population may indirectly benefit the other via reduced transmission. Due to the mobility and extensive contacts, Palestinians employed in Israel could be a prime target for vaccination. METHODS: To evaluate the epidemiological and the economic benefits conferred by vaccinating Palestinians employed in Israel, we developed a model of influenza transmission within and between Israel and the West Bank. We parameterized the contact patterns underlying transmission by conducting a survey among Palestinians employed in Israel, and integrating survey results with traffic patterns and socio-demographic data. RESULTS: Vaccinating 50% of Palestinian workers is predicted to reduce the annual influenza burden by 28,745 cases (95% CI: 15,031-50,717) and 37.7 deaths (95% CI: 19·9–65·5) for the Israeli population, and by 32,9900 cases (95% CI: 14,379-51,531) and 20.2 deaths (CI 95%: 9·8–31·5) for the Palestinian population. Further, we found that as the indirect protection was so substantial, funding such a vaccination campaign would be cost-saving from the Israeli Ministry of Health perspective. CONCLUSIONS: Offering influenza vaccination to Palestinians employed in Israel could efficiently reduce morbidity and mortality within both Israel and the Palestinian territory. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-11601-2. BioMed Central 2021-08-12 /pmc/articles/PMC8358262/ /pubmed/34384411 http://dx.doi.org/10.1186/s12889-021-11601-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yamin, Dan
Kahana, Dor
Shahmoon, Edan
Fitzpatrick, Meagan C.
Galvani, Alison P.
Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy
title Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy
title_full Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy
title_fullStr Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy
title_full_unstemmed Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy
title_short Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy
title_sort influenza vaccination should have no border: cost-effectiveness of cross-border subsidy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358262/
https://www.ncbi.nlm.nih.gov/pubmed/34384411
http://dx.doi.org/10.1186/s12889-021-11601-2
work_keys_str_mv AT yamindan influenzavaccinationshouldhavenobordercosteffectivenessofcrossbordersubsidy
AT kahanador influenzavaccinationshouldhavenobordercosteffectivenessofcrossbordersubsidy
AT shahmoonedan influenzavaccinationshouldhavenobordercosteffectivenessofcrossbordersubsidy
AT fitzpatrickmeaganc influenzavaccinationshouldhavenobordercosteffectivenessofcrossbordersubsidy
AT galvanialisonp influenzavaccinationshouldhavenobordercosteffectivenessofcrossbordersubsidy